Maternal and Infant Syphilis Prevention Act
HB3866, titled the Maternal and Infant Syphilis Prevention Act, would direct the Secretary of Health and Human Services to issue guidance within 12 months on best practices for screening and treating congenital syphilis under Medicaid and the Children’s Health Insurance Program (CHIP). The bill is framed around the sharp rise in syphilis and congenital syphilis cases nationwide and cites the severe health consequences for pregnant people, newborns, and infants, including stillbirth, infant death, and long-term developmental and neurological harm.
The guidance would be aimed at state Medicaid and CHIP agencies, as well as the Indian Health Service, Indian tribes, tribal organizations, and Urban Indian organizations. It specifically encourages states to use existing Medicaid and CHIP authorities, including section 1115 waivers, to expand screening access, improve provider and patient education, integrate telehealth, support multilingual resources and interpreter services, increase third-trimester and delivery testing, and improve treatment protocols. The bill also requires HHS to submit a public report to Congress within two years analyzing how the recommended best practices are being implemented.
The bill does not directly mandate a new federal screening requirement or create a new benefit, but it would shape state Medicaid and CHIP administration by providing federal guidance on congenital syphilis prevention. Its practical effect would be to encourage states to adopt or expand screening, education, telehealth, and treatment practices, especially for pregnant women and newborns, using existing Medicaid, CHIP, and waiver authorities. It also explicitly includes Indian health programs and urban Indian health programs, broadening the policy reach to tribal health systems and related populations.
The available context suggests the bill is generally preventive and bipartisan in tone, with support implied by its introduction by Rep. Ciscomani and Rep. Stansbury. The findings emphasize a public health crisis and the need for earlier detection and treatment, which indicates a consensus-oriented approach focused on maternal and infant health rather than controversy over ideology or spending. No votes or committee debate are provided, so there is no recorded opposition in the supplied materials.
The main policy tension appears to be between federal guidance and state variation: the bill responds to uneven state screening requirements by encouraging more consistent best practices, but it stops short of imposing a nationwide mandate. Another possible point of contention is implementation burden, since states and health systems may need to expand screening, telehealth, multilingual outreach, and provider training. The bill also references the use of Medicaid waivers and tribal health authorities, which could raise questions about administrative flexibility, funding, and how aggressively states should be expected to act.